These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 25460146)
1. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells. Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146 [TBL] [Abstract][Full Text] [Related]
2. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics. Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969 [TBL] [Abstract][Full Text] [Related]
3. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572 [TBL] [Abstract][Full Text] [Related]
4. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Dubrovska A; Elliott J; Salamone RJ; Kim S; Aimone LJ; Walker JR; Watson J; Sauveur-Michel M; Garcia-Echeverria C; Cho CY; Reddy VA; Schultz PG Clin Cancer Res; 2010 Dec; 16(23):5692-702. PubMed ID: 21138868 [TBL] [Abstract][Full Text] [Related]
7. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409 [TBL] [Abstract][Full Text] [Related]
8. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction. Wu CP; Du HD; Gong HL; Li DW; Tao L; Tian J; Zhou L Int J Oncol; 2014 May; 44(5):1652-60. PubMed ID: 24573690 [TBL] [Abstract][Full Text] [Related]
9. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445 [TBL] [Abstract][Full Text] [Related]
11. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957 [TBL] [Abstract][Full Text] [Related]
12. [Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties]. Lu RQ; Wu JG; Zhou GC; Jiang HG; Yu JW; Jiang BJ Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):174-9. PubMed ID: 22368028 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of CD133(+) human colon cancer SW620 cells. Kawamoto H; Yuasa T; Kubota Y; Seita M; Sasamoto H; Shahid JM; Hayashi T; Nakahara H; Hassan R; Iwamuro M; Kondo E; Nakaji S; Tanaka N; Kobayashi N Cell Transplant; 2010; 19(6):857-64. PubMed ID: 20587144 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice. Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113 [TBL] [Abstract][Full Text] [Related]
15. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Zhang Q; Shi S; Yen Y; Brown J; Ta JQ; Le AD Cancer Lett; 2010 Mar; 289(2):151-60. PubMed ID: 19748175 [TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Lo YL; Liu Y; Tsai JC Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284 [TBL] [Abstract][Full Text] [Related]
17. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564 [TBL] [Abstract][Full Text] [Related]
18. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139 [TBL] [Abstract][Full Text] [Related]
19. Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer. Moro M; Bertolini G; Pastorino U; Roz L; Sozzi G J Thorac Oncol; 2015 Jul; 10(7):1027-36. PubMed ID: 26020124 [TBL] [Abstract][Full Text] [Related]
20. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]